Sugi Predict

Sugi Predict / Compounds / SCHEMBL3423517

SCHEMBL3423517

SCHEMBL3423517

CC1CCCC(n2c(=O)c(C(=O)NCC(=O)O)c(O)n(C3CCCCC3)c2=O)C1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGLN1 Q9GZT9 11/20 0.83
▸ HIF1AN Q9NWT6 2/20 0.83
▸ EGLN2 Q96KS0 2/20 0.83
▸ EGLN3 Q9H6Z9 2/20 0.83
▸ OGFOD1 Q8N543 1/20 0.83
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ NPSR1 Q6W5P4 3/20 0.47
▸ XBP1 P17861 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ BBOX1 O75936 2/20 0.39
▸ ASPH Q12797 2/20 0.39
▸ KDM8 Q8N371 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ CNR1 P21554 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3423425 0.92 EGLN1 (0.97) EGLN1HIF1ANEGLN2EGLN3OGFOD1
SCHEMBL3419275 0.91 EGLN1 (0.86) EGLN1HIF1ANEGLN2EGLN3OGFOD1
SCHEMBL3419112 0.91 EGLN1 (1.00) EGLN1HIF1ANEGLN2EGLN3OGFOD1
SCHEMBL3422096 0.91 EGLN1 (1.00) EGLN1HIF1ANEGLN2EGLN3OGFOD1
SCHEMBL3421361 0.91 EGLN1 (1.00) EGLN1HIF1ANEGLN2EGLN3OGFOD1
SCHEMBL3423522 0.91 EGLN1 (1.00) EGLN1HIF1ANEGLN2EGLN3OGFOD1
SCHEMBL3422098 0.91 EGLN1 (1.00) EGLN1HIF1ANEGLN2EGLN3OGFOD1
SCHEMBL3419140 0.90 EGLN1 (0.97) EGLN1HIF1ANEGLN2EGLN3OGFOD1
Bicarbonate SCHEMBL15419071 0.90 EGLN1 (0.97) EGLN1HIF1ANEGLN2EGLN3OGFOD1
SCHEMBL3421189 0.90 EGLN1 (0.97) EGLN1HIF1ANEGLN2EGLN3OGFOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200157055-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2020-05-21 — — US claimed
EP-2037922-B9 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-08-23 — — EP claimed
EP-2037922-B1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-01-22 — — EP claimed
US-8324208-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2012-12-04 — — US claimed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 — — US claimed
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 — — US disclosed
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 — — US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 — — US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 — — US disclosed
US-20210347740-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2021-11-11 — — US disclosed
US-20210347740-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2021-11-11 — — US disclosed
US-20200157055-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2020-05-21 — — US disclosed
US-20130072487-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-03-21 — — US disclosed
US-8324208-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2012-12-04 — — US disclosed
US-8324208-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2012-12-04 — — US disclosed
US-8324208-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2012-12-04 — — US disclosed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 — — US disclosed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 — — US disclosed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 — — US disclosed
WO-2007150011-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643397-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 EGLN1 6/4885HIF1AN 1/4885EGLN2 3/4885
US-20210347740-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN1 6/4885HIF1AN 1/4885EGLN2 3/4885
US-20130072487-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 EGLN1 6/4885HIF1AN 1/4885EGLN2 3/4885
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 EGLN1 6/4885HIF1AN 1/4885EGLN2 3/4885
US-20200157055-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN1 6/4885HIF1AN 1/4885EGLN2 3/4885
US-20230227414-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN1 6/4885HIF1AN 1/4885EGLN2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.